AOD-9604, MOTS-c, and Tesamorelin Dosage: What Research Actually Shows

There is no single established dosage for AOD-9604, MOTS-c, and tesamorelin used together, because each compound is researched separately and only tesamorelin has an FDA-approved human dose. Tesamorelin is approved at 2 mg injected subcutaneously once daily for HIV-associated lipodystrophy, while AOD-9604 and MOTS-c remain research chemicals with no approved human dosing. Any combined number you see online is extrapolated from separate studies, not from a clinical guideline.

Three Different Peptides, Three Different Jobs

These compounds get grouped together because all three appear in fat-loss and metabolic research discussions, but they work through unrelated pathways.

• AOD-9604 is a modified fragment of human growth hormone (hGH 176–191) studied for its effects on fat breakdown, particularly lipolysis.
• MOTS-c is a mitochondrial-derived peptide researched for metabolic regulation, insulin sensitivity, and exercise-mimicking effects.
• Tesamorelin is a growth hormone-releasing hormone (GHRH) analog, sold as Egrifta, that raises endogenous growth hormone and IGF-1.

AOD-9604 and MOTS-c are not FDA-approved for any human use in the United States. Tesamorelin is approved, but only for a narrow indication: excess abdominal fat in adults with HIV and lipodystrophy, not general weight loss.

Research Dosage Ranges at a Glance

The numbers below come from published studies, animal models, and community-reported protocols. They are not interchangeable, and none of them has been validated in a head-to-head trial of all three compounds.

Compound	Common research dose	Frequency	FDA status
AOD-9604	250–500 mcg (some protocols up to 1 mg)	1–2 times daily, often fasted	Not approved for human use
MOTS-c	5–10 mg	1–3 times weekly in most reports	Not approved for human use
Tesamorelin	2 mg (1.4 mg for Egrifta WR)	Once daily, subcutaneous	Approved for HIV-associated lipodystrophy

AOD-9604 Dosage in Research Settings

Most AOD-9604 research protocols fall between 250 mcg and 500 mcg per injection, usually once or twice daily and often on an empty stomach. Human trials from the 2000s used doses in the low microgram range, and those studies did not show consistent, clinically meaningful fat loss on their own. Anyone researching an aod 9604 dosage should treat published microgram figures as study parameters, not as a recommended regimen.

AOD-9604 has a short half-life, which is why many protocols split the total into two smaller injections rather than one large one. That detail appears in nearly every community protocol, even though it has never been confirmed in a controlled human trial.

Why 5 mg Vials Cause Dosing Confusion

Vials are sold by total peptide weight, and 5 mg vials are the most common size for AOD-9604. A 5 mg vial contains 5,000 mcg, so when people look up an aod-9604 5mg dosage, they are almost always asking about vial size rather than a 5 mg injection. Injecting the entire contents of a 5 mg vial at once would be roughly ten times the doses used in most research protocols.

MOTS-c Dosage in Research Settings

MOTS-c has far less human data than AOD-9604, and most available evidence comes from rodent and cell studies. Reported human research doses cluster around 5 mg to 10 mg per week, sometimes split into two or three subcutaneous injections. No published trial has established a safe or effective MOTS-c dose in people.

Because MOTS-c acts on mitochondrial function rather than growth hormone signaling, it is not a like-for-like substitute for AOD-9604. The two peptides are studied for overlapping metabolic goals through completely different mechanisms.

Tesamorelin Dosage: The Only FDA-Approved Option

Tesamorelin is injected subcutaneously once daily at 2 mg, while the newer Egrifta WR formulation is dosed at 1.4 mg once daily. It is approved specifically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy, and it requires a prescription plus ongoing clinician monitoring.

Side effects reported in trials include injection site reactions, joint and muscle pain, swelling, and elevated IGF-1 levels. Tesamorelin can also affect blood sugar, which matters for people with diabetes or prediabetes.

AOD-9604 vs Tesamorelin: The Regulatory Gap

Comparing aod 9604 vs tesamorelin is mostly a comparison of evidence quality. Tesamorelin has completed Phase 3 trials, carries an FDA approval, and comes with a defined dose, a monitoring plan, and a known side effect profile. AOD-9604 has small, older human studies, no approval, and no standardized product quality.

That gap matters in practice. A patient can obtain tesamorelin through a licensed prescriber, while AOD-9604 is typically purchased from research chemical vendors with no guarantee of purity or actual peptide content.

Can You Stack AOD-9604, MOTS-c, and Tesamorelin?

No clinical trial has tested an aod-9604 mots-c tesamorelin stack, and no medical organization publishes a combined dosing protocol. People who research aod 9604 and mots-c together often assume that different mechanisms simply add up, but that assumption has never been verified in humans.

Stacking also makes side effects harder to trace. If a reaction occurs, there is no reliable way to identify which compound caused it, and the uncertainty grows when a prescription drug like tesamorelin is combined with unregulated research chemicals.

Safety and Legal Considerations

• AOD-9604 and MOTS-c are sold as research chemicals and are not approved for human consumption in the United States.
• Peptide products are frequently mislabeled, underdosed, or contaminated; a third-party certificate of analysis helps but does not guarantee safety.
• Tesamorelin requires a prescription, and importing or self-sourcing it outside a pharmacy is illegal in most US states.
• Anyone considering these compounds should talk with a healthcare professional, especially people who are pregnant, nursing, taking medication, or managing a chronic condition.

The clearest conclusion is also the least exciting: dosing figures for these three peptides come from separate research contexts and cannot be merged into a reliable combined protocol. No dosage of AOD-9604 or MOTS-c has been demonstrated to be safe and effective in humans.

COMMON QUESTIONS

Frequently Asked Questions

What is the typical AOD-9604 dosage used in research?

Most AOD-9604 research protocols use roughly 250 mcg to 500 mcg per injection, often once or twice daily on an empty stomach. Those figures come from small, older human studies and animal models rather than a confirmed clinical regimen. AOD-9604 is not FDA-approved for human use in the United States.

Is tesamorelin FDA-approved for weight loss?

No. Tesamorelin is approved only for reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy, at 2 mg daily or 1.4 mg daily for Egrifta WR. It is a prescription drug and is not approved as a general weight-loss treatment.

Can AOD-9604, MOTS-c, and tesamorelin be stacked safely?

No clinical trial has tested AOD-9604, MOTS-c, and tesamorelin as a combination, so there is no evidence-based dosing protocol. Stacking a prescription drug with unapproved research chemicals also makes it very difficult to identify which compound is causing a side effect. Anyone considering this combination should speak with a healthcare professional first.